These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7807730)

  • 1. [A longitudinal study of CMRGlu in dementia of Alzheimer type].
    Kuwabara Y; Ichiya Y; Ichimiya A; Sasaki M; Akashi Y; Yoshida T; Fukumura T; Masuda K
    Kaku Igaku; 1994 Oct; 31(10):1255-60. PubMed ID: 7807730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET.
    Piert M; Koeppe RA; Giordani B; Berent S; Kuhl DE
    J Nucl Med; 1996 Feb; 37(2):201-8. PubMed ID: 8667045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study.
    Del Sole A; Clerici F; Chiti A; Lecchi M; Mariani C; Maggiore L; Mosconi L; Lucignani G
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1357-66. PubMed ID: 18418593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease.
    Piert M; Koeppe RA; Giordani B; Minoshima S; Kuhl DE
    J Nucl Med; 1996 Jul; 37(7):1115-22. PubMed ID: 8965180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cerebral glucose metabolism in dementia (PET-FDG study)].
    Hatazawa J; Itoh M; Matsuzawa T
    Rinsho Hoshasen; 1989 Oct; 34(11):1343-8. PubMed ID: 2601096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [F-18 FDG PET in dementia].
    Ichiya Y
    Rinsho Hoshasen; 1989 Oct; 34(11):1337-41. PubMed ID: 2601095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia.
    Benson DF; Kuhl DE; Hawkins RA; Phelps ME; Cummings JL; Tsai SY
    Arch Neurol; 1983 Nov; 40(12):711-4. PubMed ID: 6605139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids.
    Fulham MJ; Brunetti A; Aloj L; Raman R; Dwyer AJ; Di Chiro G
    J Neurosurg; 1995 Oct; 83(4):657-64. PubMed ID: 7674016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of cerebral glucose utilization in dementia.
    Matsuzawa T; Matsui H; Meguro K; Ueda M; Yamada K; Yamaguchi T; Itoh M; Hatazawa J; Kinomura S
    Sci Rep Res Inst Tohoku Univ Med; 1990 Dec; 37(1-4):11-21. PubMed ID: 2103655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method.
    Kuhl DE; Metter EJ; Riege WH; Phelps ME
    J Cereb Blood Flow Metab; 1982; 2(2):163-71. PubMed ID: 6978885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronal reconstruction images of glucose metabolism in Alzheimer's disease.
    Fukuyama H; Harada K; Yamauchi H; Miyoshi T; Yamaguchi S; Kimura J; Kameyama M; Senda M; Yonekura Y; Konishi J
    J Neurol Sci; 1991 Dec; 106(2):128-34. PubMed ID: 1802960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity.
    Vander Borght T; Minoshima S; Giordani B; Foster NL; Frey KA; Berent S; Albin RL; Koeppe RA; Kuhl DE
    J Nucl Med; 1997 May; 38(5):797-802. PubMed ID: 9170449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.
    Small GW; Mazziotta JC; Collins MT; Baxter LR; Phelps ME; Mandelkern MA; Kaplan A; La Rue A; Adamson CF; Chang L
    JAMA; 1995 Mar 22-29; 273(12):942-7. PubMed ID: 7884953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The relationship between the cerebral blood flow, oxygen consumption and glucose metabolism in primary degenerative dementia].
    Kuwabara Y; Ichiya Y; Ichimiya A; Sasaki M; Akashi Y; Yoshida T; Fukumura T; Masuda K
    Kaku Igaku; 1995 Mar; 32(3):253-62. PubMed ID: 7739155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical stages in subjects at risk for neurological disorders: can PET-FDG tell us more?
    Azari NP; Pietrini P
    J Neurol; 1995 Jan; 242(2):112-4. PubMed ID: 7707087
    [No Abstract]   [Full Text] [Related]  

  • 16. Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose.
    Heiss WD; Pawlik G; Herholz K; Wagner R; Göldner H; Wienhard K
    J Cereb Blood Flow Metab; 1984 Jun; 4(2):212-23. PubMed ID: 6609929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study.
    Roelcke U; Kappos L; Lechner-Scott J; Brunnschweiler H; Huber S; Ammann W; Plohmann A; Dellas S; Maguire RP; Missimer J; Radü EW; Steck A; Leenders KL
    Neurology; 1997 Jun; 48(6):1566-71. PubMed ID: 9191767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer-type dementia.
    Koss E; Friedland RP; Ober BA; Jagust WJ
    Am J Psychiatry; 1985 May; 142(5):638-40. PubMed ID: 3872604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18F-fluorodeoxyglucose positron emission tomography in Parkinson's disease].
    Arahata Y; Kato T; Tadokoro M; Sobue G
    Nihon Rinsho; 1997 Jan; 55(1):222-6. PubMed ID: 9014454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-resolution PET studies in Alzheimer's disease.
    Kumar A; Schapiro MB; Grady C; Haxby JV; Wagner E; Salerno JA; Friedland RP; Rapoport SI
    Neuropsychopharmacology; 1991 Jan; 4(1):35-46. PubMed ID: 2003867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.